We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Meningitis Vaccine Continues to Prove Effective in Phase 3 Studies
Pfizer’s Meningitis Vaccine Continues to Prove Effective in Phase 3 Studies
Pfizer has released positive topline results of two Phase 3 studies of its meningitis vaccine Trumenba, saying its ability to provoke an immune response and safety data are consistent with the findings that formed the basis for its FDA accelerated approval.